Wolfe Research analyst Bill Carcache downgrades Capital One Financial (NYSE:COF) from Peer Perform to Underperform and announces $86 price target.
Kymera Therapeutics Received FDA Orphan Drug Designation for Treatment of Peripheral T-cell Lymphoma
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=879422